spacer
home > > spring 2002 > vitro preclinical lead optimisation technologies (plots) in pharmaceutical development
PUBLICATIONS


Vitro Preclinical Lead Optimisation Technologies (PLOTs) in Pharmaceutical Development

Sensible lead candidate selection for preclinical drug development and registration should reduce the high rate of attrition, the cost of which increases with the distance that the failed candidate has proceeded down the R&D pipeline. Rates of attrition are especially high during the early regulatory preclinical toxicology and clinical phases of testing. Not surprisingly, because of the large number of hits identified from primary high throughput discovery screens, lead candidate identification has emerged as a critical decision-making milestone. In short, there is a need for early, rapid and robust preclinical lead optimisation technology (PLOT) screening assays which will allow a lead series of compounds to be ranked for desirable or undesirable characteristics.

These PLOTs (1) must be sufficiently rapid to interface with high throughput discovery screens without creating a further bottleneck, be predictive of drug failure and be cost-effective (see Figure 1). The assays which constitute the PLOT platform are typically in vitro systems, miniaturised and amenable to automation, thereby achieving the required throughput with minimal compound use - another crucial factor for facilitating the process of lead optimisation (see Figure 2). Industry recognition of the '3 Rs' (Reduction, Refinement and Replacement) through the implementation of the ethical review process (ERP), has been instrumental in the increasing acceptance and incorporation of alternative in vitro models, especially in early drug development projects.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Professor Chris Atterwill, Director of the Biosciences Division at Huntingdon Life Sciences

Professor Chris Atterwill trained as a Pharmacist at the University of London and gained a PhD in Pharmacology. Having completed three postdoctoral positions with the MRC and the University of Oxford, he took up a position as Head of In Vitro Toxicology at SmithKline and French and subsequently gained his FRCPath and FRPharmS through his work in promoting and developing animal alternative technologies in toxicology.

He then moved to the position of Chair in Biosciences at the University of Hertfordshire and later became Head of Preclinical Drug Safety at Roche Discovery UK. He joined Huntingdon Life Sciences in 1999 where he is the Director of the Biosciences Division. He also serves on the UK Government Home Office Animal Procedures Committee (APC).

spacer
Professor Chris Atterwill
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Engineered llama antibodies neutralise Covid-19 virus

Researchers have developed a family of engineered nanobodies which neutralise the SARS-CoV-2 virus, targeting the viral spike protein in a novel way.
More info >>

White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement